HAS2 and breast cancer: These analyses reveal that in contrast to TGFβ, rhPRG4 leads to reduction in the protein abundance of CD44 and HAS2 in the absence or presence of exogenous TGFβ, which could provide a mechanism by which rhPRG4 suppresses TGFβ-induced invasiveness of breast cancer cells.